ATE291927T1 - Peptide zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen - Google Patents

Peptide zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen

Info

Publication number
ATE291927T1
ATE291927T1 AT00947924T AT00947924T ATE291927T1 AT E291927 T1 ATE291927 T1 AT E291927T1 AT 00947924 T AT00947924 T AT 00947924T AT 00947924 T AT00947924 T AT 00947924T AT E291927 T1 ATE291927 T1 AT E291927T1
Authority
AT
Austria
Prior art keywords
disorders
treatment
interpersonal
environment
peptides
Prior art date
Application number
AT00947924T
Other languages
English (en)
Inventor
Tony Marcel
Francois Rougeon
Catherine Rougeot
Original Assignee
Pasteur Institut
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Centre Nat Rech Scient filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE291927T1 publication Critical patent/ATE291927T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Radiation-Therapy Devices (AREA)
AT00947924T 1999-06-23 2000-06-22 Peptide zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen ATE291927T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14056399P 1999-06-23 1999-06-23
PCT/EP2000/006259 WO2001000221A2 (en) 1999-06-23 2000-06-22 Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders

Publications (1)

Publication Number Publication Date
ATE291927T1 true ATE291927T1 (de) 2005-04-15

Family

ID=22491816

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00947924T ATE291927T1 (de) 1999-06-23 2000-06-22 Peptide zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen
AT05006494T ATE414529T1 (de) 1999-06-23 2000-06-22 Zusammensetzungen zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT05006494T ATE414529T1 (de) 1999-06-23 2000-06-22 Zusammensetzungen zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen

Country Status (14)

Country Link
US (2) US7387778B2 (de)
EP (2) EP1185294B1 (de)
JP (1) JP2003512302A (de)
CN (1) CN1189211C (de)
AT (2) ATE291927T1 (de)
AU (1) AU6154700A (de)
CA (1) CA2376935A1 (de)
CY (1) CY1108745T1 (de)
DE (2) DE60040878D1 (de)
DK (2) DK1593387T3 (de)
ES (2) ES2315753T3 (de)
NZ (1) NZ516477A (de)
PT (2) PT1185294E (de)
WO (1) WO2001000221A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589750B2 (en) * 1997-02-20 2003-07-08 Institut Pasteur Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
JP2003512302A (ja) 1999-06-23 2003-04-02 アンスティテュ パストゥール 障害性個人間及び行動障害の治療のための治療法及び組成物
ATE288763T1 (de) * 2000-12-22 2005-02-15 Pasteur Institut Prozess zum screening von molekülen, die spezifisch an die nep-bindungsstelle des qhnpr- pentapeptides binden
CN101787073B (zh) 2003-01-28 2013-12-25 艾恩伍德医药品股份有限公司 治疗胃肠病的方法和组合物
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ES2390075T3 (es) * 2004-03-19 2012-11-06 Institut Pasteur Péptidos derivados de la proteína BPLP humana, polinucleótidos que codifican dichos péptidos y anticuerpos dirigidos contra dichos péptidos
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8034782B2 (en) 2008-07-16 2011-10-11 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
LT2274321T (lt) 2008-04-07 2019-03-12 Institut Pasteur Opiorfino peptido dariniai kaip potencialūs enkefaliną skaldančių ektopeptidazių inhibitoriai
FR2931362B1 (fr) * 2008-05-26 2017-08-18 Pasteur Institut L'opiorphine pour une utilisation en tant que psychostimulant.
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
CA2645452A1 (en) * 2008-11-28 2010-05-28 Institut Pasteur Use of basic prolin-rich lacrimal gene products, such as opiorphin, as a biomarker
CA2994066A1 (en) 2008-12-03 2010-06-10 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
DE102009039655B3 (de) 2009-09-02 2011-03-31 ITT Mfg. Enterprises, Inc., Wilmington UV-Desinfektionseinrichtung für Abwasser und Trinkwasser mit einer Reinigungsvorrichtung
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2681236B1 (de) 2011-03-01 2018-01-03 Synergy Pharmaceuticals Inc. Verfahren zur herstellung von guanylat-cyclase-c-agonisten
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
GB201607814D0 (en) 2016-05-04 2016-06-15 5D Health Prot Group Ltd Anti-microbial compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8327966D0 (en) * 1983-10-19 1983-11-23 Nyegaard & Co As Chemical compounds
FR2637600B1 (fr) * 1988-10-11 1992-03-06 Pasteur Institut Peptides et polypeptides provenant de la glande sous maxillaire du rat, anticorps monoclonaux et polyclonaux correspondants, hybridomes correspondants et applications de ces produits au diagnostic, a la detection ou a des fins therapeutiques
US5589189A (en) * 1994-09-14 1996-12-31 Nexstar Pharmaceuticals, Inc. Liposome dispersion
US6589750B2 (en) * 1997-02-20 2003-07-08 Institut Pasteur Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
KR100353014B1 (ko) 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
US6455564B1 (en) * 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
JP2003512302A (ja) 1999-06-23 2003-04-02 アンスティテュ パストゥール 障害性個人間及び行動障害の治療のための治療法及び組成物
ATE288763T1 (de) 2000-12-22 2005-02-15 Pasteur Institut Prozess zum screening von molekülen, die spezifisch an die nep-bindungsstelle des qhnpr- pentapeptides binden

Also Published As

Publication number Publication date
PT1185294E (pt) 2005-08-31
EP1185294A2 (de) 2002-03-13
JP2003512302A (ja) 2003-04-02
US20030186870A1 (en) 2003-10-02
CY1108745T1 (el) 2014-04-09
ES2315753T3 (es) 2009-04-01
DK1593387T3 (da) 2009-03-02
DK1185294T3 (da) 2005-08-01
DE60019106D1 (de) 2005-05-04
CN1189211C (zh) 2005-02-16
NZ516477A (en) 2004-02-27
ES2238299T3 (es) 2005-09-01
EP1185294B1 (de) 2005-03-30
US7387778B2 (en) 2008-06-17
ATE414529T1 (de) 2008-12-15
WO2001000221A3 (en) 2001-05-03
DE60019106T2 (de) 2006-02-16
EP1593387A1 (de) 2005-11-09
AU6154700A (en) 2001-01-31
CA2376935A1 (en) 2001-01-04
PT1593387E (pt) 2009-03-18
WO2001000221A2 (en) 2001-01-04
CN1356906A (zh) 2002-07-03
DE60040878D1 (de) 2009-01-02
US20030078200A1 (en) 2003-04-24
EP1593387B1 (de) 2008-11-19

Similar Documents

Publication Publication Date Title
ATE291927T1 (de) Peptide zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen
WO2004019884A3 (en) Agents and methods for enhancing bone formation
ATE430193T1 (de) Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
ATE265213T1 (de) Noribogain zur behandlung von schmerzen und drogenabhängigkeit
DE60227658D1 (de) Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren
HRP20020593B1 (en) Brain, spinal and nerve injury treatment
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DE60333857D1 (de) Oxytocin zur Behandlung von Autismus und Asperger-Syndrom
BR0015698A (pt) Composições e métodos para tratamento de doenças alérgicas
DE69929464D1 (de) Zyklische polyamine zur behandlung der thrombozytopenie
WO2005020928A3 (en) Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
DE60008143D1 (de) Lipoxin-a4 und deren analoge zur behandlung von trockenen augen
DE60008753D1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
DE69927147D1 (de) Verwendung von osteoprotegerin zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE602004023762D1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren
ATE541565T1 (de) Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus
ATE355054T1 (de) Verfahren und verbindungen zur behandlung der depression
DE602004028574D1 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
ATE296635T1 (de) Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten
DE60018704D1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
MXPA04010816A (es) Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1185294

Country of ref document: EP